CliffBio
biologic

Hympavzi

marstacimab-hncq

Loss of exclusivityOctober 2036projected — 12-year biologic exclusivity estimate
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameHympavzi
Active ingredientmarstacimab-hncq
Strength150MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2024
Marketing statusRx

More from Pfizer

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hympavzi patent cliff — loss of exclusivity October 2036 | CliffBio